Diagnostic antibodies and antigens for functional ELISA assay kit, lateral flow and other immunoassays in diagnostics
Diagnostic antibodies and antigens list
In vitro diagnostic (IVD) testing has become an indispensable tool in clinical practice for
diagnosing and monitoring of diseases, as well as providing prognosis and predicting treatment
response, In vitro tests may be done in laboratories, health care facilities or even in the home.
The tests themselves can be performed on a variety of instruments ranging from small, handheld tests
to complex laboratory instruments. They allow doctors to diagnose patients effectively and work to
provide appropriate treatments.
IVDs are used to analyze human samples such as blood and saliva, either by measuring the
concentration of specific substances, or analytes (such as sodium and cholesterol), or by detecting
the presence or absence of a particular marker or set of markers, such as a genetic mutation or an
immune response to infection. Clinicians regularly use IVDs to diagnose conditions, guide treatment
decisions, and even mitigate or prevent future disease (for example, through screening tests that
indicate a patient’s risk of developing a given condition in the future). There are over 40,000
different IVD products available that provide information to doctors and patients on a huge range of
conditions. These comprise markers for inorganic chemistry (electrolytes, toxins, and heavy metals),
markers for organic chemistry/biochemistry (proteins, lipids, and carbohydrates), as well as
molecular biologic procedures (sequencing and polymerase chain reaction).
In recent years, the value of IVDs has gained further recognition because of their potential to save
lives through earlier diagnosis of medical conditions. In the case of an infectious disease, early
detection can ensure that patients receive timely care to help slow or stop the progression of
disease. Further, knowledge of infection can help promote self-isolation to prevent further spread
of the disease to the community. This has been particularly important in containing the spread of
highly infectious agents during an active outbreak. Using IVDs to predict underlying genetic
conditions in addition to diagnostic screening can also prevent unnecessary suffering by a patient
as well as reduce the scale of treatment required.
As the ease-of-use and reliability of IVDs has improved, some IVDs have moved out of the laboratory
setting and into the patient’s home. Consumers can now perform simple tests to monitor blood glucose
levels, identify urinary tract infections, track ovulation, and confirm pregnancy. These tests not
only empower individuals to take charge of their own health but can provide quick results that help
guide further medical actions. Genemedi provides diagnostic antibodies and antigens for the in vitro
diagnosis of diseases such as infectious disease, inflammation/autoimmune/inflammatory disease,
kidney function (renal damages), liver diseases, lung injury, metabolic diseases, multiple disease,
neurodegenerative diseases, pain, thyroid diseases, vitamin deficiency and so on.
Evidence has shown plasma biomarkers (p-tau181, p-tau217, p-tau231, p-tau202 and 205, p-tau212 and
214, p-tau413, p-tau422, GFAP, NfL, and Aβ42/40) were significantly changed in preclinical
Alzheimer's Disease (AD). Recently, our R&D department demonstrated that our GMP-h-p-tau217-Ab01 has
a large linear range and good sensitivity against the GMP-h-p-tau217-Ag01. Below is the result of
GeneMedi's GMP-h-p-tau217-Ab01 (Anti-human p-tau217 antibody) validation with GMP-h-p-tau217-Ag01
(p-tau217 antigen) in ELISA. We highly recommend the Ab&Ag to you.
Figure 1. GeneMedi's GMP-h-p-tau217-Ab01 (Anti-human p-tau217 antibody) is validated to detect
the GMP-h-p-tau217-Ag01 (p-tau217 antigen) in ELISA. EC50 = 25.85ng/ml.
Classification of IVD Disease:
Cancer
Infectious Disease
Inflammation/Autoimmune/Inflammatory Disease
Cardiovascular Disease
Liver Diseases
Lung Injury
Kidney Function (renal
damages)
Gastric Disease
Thyroid Diseases
Bowel Disease
Fertility
Diabetes Diseases
Metabolic Diseases
Hormone Disorders
Vitamin Deficiency
Fibrinogen Disorders
Neurodegenerative
Diseases
Epilepsy
Pain
Multiple Disease
Biology
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis
of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their
antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and
their antibodies-based detection of cancer have the advantages such as low-cost, and simple access,
which attracted much attention for early cancer detection. For several reasons, tumor marker itself
is typically insufficient to analyze disease conditions. Because, maximum number of markers have
been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries,
testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung,
neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary
dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis,
Parget's diseases and so on have been identified using specific marker. Detecting the quantity of
marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA),
colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric
inhibition immuno assay (TINIA), immunonephelometry and POCT.